On May 11, 2023 Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
On June 27, 2022 A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induced potent growth inhibitory antibodies
On April 14, 2021 Accelerated phase 1a/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses
On February 4, 2020 PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomized, double-blind, placebo-controlled study
On January 31, 2020 Immunization with full-length Plasmodium falciparum merozoite surface proetin 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial
On January 10, 2019 First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Cnadidate to Prevent Pregnancy-associated Malaria